Dec 01, 2021 / 06:00PM GMT
Christopher Joseph Raymond - Piper Sandler & Co., Research Division - MD & Senior Research Analyst
Great. Let's go ahead and get started with our next session. Thanks, everybody, for dialing in. My name is Chris Raymond. I'm one of the biotech analysts here at Piper Sandler. It's my pleasure to introduce our next company, which needs no introduction. We have with us Amgen today.
With us from the company is Peter Griffith, EVP and CFO; Murdo Gordon, who's the Executive Vice President of Global Commercial Operations. And of course, we also have Arvind Sood, who heads up the Investor Relations group at Amgen. So thanks, guys, for joining us.
For folks who are dialing in just some really quick housekeeping. We do have an option on your Zoom link to ask a question, I think it should be hopefully easy to understand. If you want to ask a question, please register it. I'm monitoring that as we go through our session. You don't want to do that and you just want to do an old school, just hit me on e-mail. I'm monitoring that as well. And I'll make sure your questions get asked and answered
Amgen Inc at Piper Sandler Healthcare Conference (Virtual) Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot